Cargando…

Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawe, Rispah T., Kerper, Maggie, Badve, Sunil, Li, Jun, Sandoval-Cooper, Mayra, Xie, Jingmeng, Shi, Zonggao, Patel, Kirtika, Chumba, David, Ofulla, Ayub, Prosperi, Jenifer, Taylor, Katherine, Stack, M. Sharon, Mining, Simeon, Littlepage, Laurie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787041/
https://www.ncbi.nlm.nih.gov/pubmed/26964534
http://dx.doi.org/10.1186/s12885-016-2204-6
_version_ 1782420644921606144
author Sawe, Rispah T.
Kerper, Maggie
Badve, Sunil
Li, Jun
Sandoval-Cooper, Mayra
Xie, Jingmeng
Shi, Zonggao
Patel, Kirtika
Chumba, David
Ofulla, Ayub
Prosperi, Jenifer
Taylor, Katherine
Stack, M. Sharon
Mining, Simeon
Littlepage, Laurie E.
author_facet Sawe, Rispah T.
Kerper, Maggie
Badve, Sunil
Li, Jun
Sandoval-Cooper, Mayra
Xie, Jingmeng
Shi, Zonggao
Patel, Kirtika
Chumba, David
Ofulla, Ayub
Prosperi, Jenifer
Taylor, Katherine
Stack, M. Sharon
Mining, Simeon
Littlepage, Laurie E.
author_sort Sawe, Rispah T.
collection PubMed
description BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. METHODS: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. RESULTS: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis. Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue. CONCLUSIONS: We identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2204-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4787041
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47870412016-03-12 Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration Sawe, Rispah T. Kerper, Maggie Badve, Sunil Li, Jun Sandoval-Cooper, Mayra Xie, Jingmeng Shi, Zonggao Patel, Kirtika Chumba, David Ofulla, Ayub Prosperi, Jenifer Taylor, Katherine Stack, M. Sharon Mining, Simeon Littlepage, Laurie E. BMC Cancer Research Article BACKGROUND: Breast cancer incidence and mortality vary significantly among different nations and racial groups. African nations have the highest breast cancer mortality rates in the world, even though the incidence rates are below those of many nations. Differences in disease progression suggest that aggressive breast tumors may harbor a unique molecular signature to promote disease progression. However, few studies have investigated the pathology and clinical markers expressed in breast tissue from regional African patient populations. METHODS: We collected 68 malignant and 89 non-cancerous samples from Kenyan breast tissue. To characterize the tumors from these patients, we constructed tissue microarrays (TMAs) from these tissues. Sections from these TMAs were stained and analyzed using immunohistochemistry to detect clinical breast cancer markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) status, Ki67, and immune cell markers. RESULTS: Thirty-three percent of the tumors were triple negative (ER-, PR-, HER2-), 59 % were ER+, and almost all tumors analyzed were HER2-. Seven percent of the breast cancer patients were male, and 30 % were <40 years old at diagnosis. Cancer tissue had increased immune cell infiltration with recruitment of CD163+ (M2 macrophage), CD25+ (regulatory T lymphocyte), and CD4+ (T helper) cells compared to non-cancer tissue. CONCLUSIONS: We identified clinical biomarkers that may assist in identifying therapy strategies for breast cancer patients in western Kenya. Estrogen receptor status in particular should lead initial treatment strategies in these breast cancer patients. Increased CD25 expression suggests a need for additional treatment strategies designed to overcome immune suppression by CD25+ cells in order to promote the antitumor activity of CD8+ cytotoxic T cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2204-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-10 /pmc/articles/PMC4787041/ /pubmed/26964534 http://dx.doi.org/10.1186/s12885-016-2204-6 Text en © Sawe et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sawe, Rispah T.
Kerper, Maggie
Badve, Sunil
Li, Jun
Sandoval-Cooper, Mayra
Xie, Jingmeng
Shi, Zonggao
Patel, Kirtika
Chumba, David
Ofulla, Ayub
Prosperi, Jenifer
Taylor, Katherine
Stack, M. Sharon
Mining, Simeon
Littlepage, Laurie E.
Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title_full Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title_fullStr Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title_full_unstemmed Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title_short Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration
title_sort aggressive breast cancer in western kenya has early onset, high proliferation, and immune cell infiltration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787041/
https://www.ncbi.nlm.nih.gov/pubmed/26964534
http://dx.doi.org/10.1186/s12885-016-2204-6
work_keys_str_mv AT sawerispaht aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT kerpermaggie aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT badvesunil aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT lijun aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT sandovalcoopermayra aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT xiejingmeng aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT shizonggao aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT patelkirtika aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT chumbadavid aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT ofullaayub aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT prosperijenifer aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT taylorkatherine aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT stackmsharon aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT miningsimeon aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration
AT littlepagelauriee aggressivebreastcancerinwesternkenyahasearlyonsethighproliferationandimmunecellinfiltration